Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Eclinicalmedicine|April 28, 2023
Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human studyMichael Haude, Adrian Wlodarczak, René J van der Schaaf, et al.
Lancet (London, England)|October 17, 2015
Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trialMichael Haude, Hüseyin Ince, Alexandre Abizaid, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|August 8, 2021
Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 YearsMichael Haude, Ralph Toelg, Pedro Alves Lemos, et al.
JACC. Cardiovascular Interventions|February 7, 2025
Randomized Trial of Biolimus DCB for In-Stent Restenosis: The Primary Results of the REFORM StudyRobert A Byrne, Joo-Yong Hahn, Peter O'Kane, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 19, 2023
A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human studyMichael Haude, Adrian Wlodarczak, René J van der Schaaf, et al.
European Heart Journal|May 19, 2016
Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trialMichael Haude, Hüseyin Ince, Alexandre Abizaid, et al.
American Heart Journal|October 8, 2020
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stentMarco Valgimigli, Davide Cao, Rajendra R Makkar, et al.
The American Journal of Cardiology|December 9, 2022
Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical PracticeUwe Zeymer, Ralph Toelg, Harm Wienbergen, et al.
Herz|March 4, 2022
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in GermanyUwe Zeymer, Ralph Toelg, Harm Wienbergen, et al.
Circulation. Cardiovascular Interventions|March 1, 2021
Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting StentAjay J Kirtane, Robert Stoler, Robert Feldman, et al.
Pageof 11